ETON: Record Q2 revenue and raised 2026 guidance reflect strong rare disease portfolio momentum
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 99% revenue growth to $37.6M, with net income of $11.6M and Adjusted EBITDA of $16.2M. Guidance for 2026 revenue was raised to over $145M, driven by strong rare disease portfolio performance and new product launches.Original document: Eton Pharmaceuticals, Inc. [ETON] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 99% revenue growth to $37.6M, with net income of $11.6M and Adjusted EBITDA of $16.2M. Guidance for 2026 revenue was raised to over $145M, driven by strong rare disease portfolio performance and new product launches.
Original document: Eton Pharmaceuticals, Inc. [ETON] SEC 8-K Current Report — Aug. 13 2026